A new study conducted by scientists from the Dana-Farber Cancer Institute at Harvard Medical School and Karolinska Institutet presents very promising results for the treatment of the cancer form multiple myeloma.
The drug candidate used in the research has been developed by scientists from Karolinska Institutet and a Swedish company following its initial identification at the same university. The findings are so promising that the scientists are teaming up with Harvard to bring the drug to clinical trials on patients.
The journal Blood has published a new study on a drug candidate for multiple myeloma, a form of cancer that affects about one per cent of all tumour patients, with some 600 people a year developing the disease in Sweden. Multiple myeloma is a life-threatening disease and there is a dire medical need for new therapies, especially for the patients whose tumour cells have become resistant to the conventional drugs.
“The discovery that our substance works on multiple myeloma cells resistant to conventional therapy is very promising for the future, says Professor Stig Linder at Karolinska Institutet’s Department of Oncology-Pathology. “We’re now very hopeful that we and our colleagues at Harvard Medical School will be able to develop an effective treatment.”
The study demonstrates that the drug candidate, called VLX1570, inhibits tumour growth and prolongs survival in preclinical multiple myeloma models. The exact mechanism of action of the substance was identified earlier at Karolinska Institutet (Nature Medicine, 2011). Put simply, the tumour cells can be said to be more sensitive than normal cells to disruption to the machinery that breaks down defective proteins. When this machinery is blocked, it triggers apoptosis (programmed cell death) in the tumour cells.
“We show that the drug candidate kills multiple myeloma cells from cancer patients,” says Professor Linder. “The substance is also effective against myeloma cells that have developed a resistance to the clinically used drug bortezomib.”
Dr Dharminder Chauhan at Harvard Medical School says that the mechanism of action is very interesting as regards the development of new cancer drugs and adds, “We’re delighted to be able to study the therapeutic potential of this new drug candidate in clinical studies. We hope that the joint research we’re doing will lead to improved cancer treatments.”
The study also found that the new substance could be combined synergistically with other cancer therapies. Karolinska Institutet and Harvard Medical School are due to launch a large-scale clinical study next year in association with drug discovery company Vivolux AB (Uppsala, Sweden).
“If the study proves successful it will represent a great step forward, mainly for all cancer patients but also for the Swedish drug industry,” says Professor Linder.
The Latest on: Cancer therapies
- Our Chicago: Blood cancer in America, reading symptoms, new treatmentson June 13, 2021 at 8:36 am
Last year, thousands of Americans were diagnosed with blood cancers, and over a million are either living with these cancers or are in remission.
- Compassion During Cancer Treatmenton June 13, 2021 at 8:00 am
A patient wrote about the smile and hug he received every time he went for a doctor’s visit, in addition to the wealth of information she provided whenever he had questions related to his cancer.
- Alpha Tau Gets FDA Breakthrough Device Designation For Cancer Therapyon June 12, 2021 at 10:55 pm
Alpha Tau developed a breakthrough cancer treatment called Alpha DaRT (Dіffusіng Alpha-emіtters Radіatіon Therapy).
- Cancer Treatment Centers launches Women's Cancer Centeron June 12, 2021 at 2:03 pm
ATLANTA — Cancer Treatment Centers of America Atlanta has launched a Women's Cancer Center, led by an experienced roster of fellowship-trained, board-certified physicians and clinicians with expertise ...
- With Help Of Alex's Lemonade Stand Foundation, 2-Year-Old Kade Fuller Finishes Treatment For Eye Canceron June 11, 2021 at 2:02 pm
A Stand For Hope TelethonThe telethon raises money for childhood cancer research and for the families dealing with a cancer diagnosis. 4 hours ago Philadelphia Weather: Scattered Showers AroundLlarisa ...
- With Help Of Alex’s Lemonade Stand Foundation, 2-Year-Old Kade Fuller Finishes Treatment For Form Of Eye Canceron June 11, 2021 at 2:00 pm
Treatments that were miles and miles away from home, and they got there with the help of Alex’s Lemonade Stand Foundation. Like many 2-year-olds, Kade loves Paw Patrol and Marvel superhero movies. But ...
- Muscogee Nation to buy former Cancer Treatment Centers of America facilityon June 11, 2021 at 12:00 pm
The Muscogee Nation National Council voted 12-0 Thursday evening to purchase the former Cancer Treatment Centers of America facility in south Tulsa.
- Promising ovarian cancer treatment proves effective and efficienton June 11, 2021 at 9:22 am
Preclinical trials of a new radiopharmaceutical to treat ovarian cancer have produced successful results, dramatically limiting tumor growth and decreasing tumor mass. Designed specifically for ...
- Two new technologies that could change cancer treatmenton June 10, 2021 at 4:34 am
By studying the biomechanics of cancer in the breast and bladder, the Mechano-Control and Edit projects are developing new ways of cancer identification and treatment that could open up new avenues in ...
- World's first blood test for real-time monitoring of cancer treatment successon June 7, 2021 at 5:40 am
Cancer patients who are undergoing targeted therapy can look forward to a new blood test that could tell their doctors whether the treatment is working, within one day after the start of the treatment ...
via Bing News
The Latest on: Multiple myeloma
- Daratumumab Plus Standard of Care Continues to Improve Survival in Newly Diagnosed Multiple Myelomaon June 12, 2021 at 9:30 am
The addition of daratumumab to lenalidomide and dexamethasone continued to reduced the risk of death by 32% compared with Rd alone in patients with newly diagnosed multiple myeloma who are transplant ...
- Janssen Announces Results from Phase 3 MAIA Study…on June 12, 2021 at 1:00 am
After nearly five years of follow-up, median progression-free survival was not reached, and a significant overall survival benefit was observed; data will be presented as a late-breaking abstract at ...
- EHA: Johnson & Johnson, nearing Sanofi showdown, bolsters Darzalex's myeloma lead with 'unprecedented' survival dataon June 12, 2021 at 12:00 am
Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, as the competition's slated to ...
- Evolving Treatment Options for Relapsed/Refractory Multiple Myelomaon June 11, 2021 at 12:06 pm
Drs Hoffman and Richter discuss a promising new treatment for patients with relapsed/refractory multiple myeloma who are not eligible for a clinical trial after 4 lines of therapy.
- FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myelomaon June 11, 2021 at 10:52 am
On August 5, 2020, the Food and Drug Administration granted accelerated approval to belantamab mafodotin-blmf (Blenrep, GlaxoSmithKline) for adult patients with relapsed or refractory multiple myeloma ...
- Clinical Trial Results Need to Be Supplemented With Real-World Data in Multiple Myelomaon June 11, 2021 at 8:25 am
The populations represented in randomized controlled trials often do not match the populations being treated in the real world due to eligibility criteria, which can be challenging when translating ...
- Novel Injectable Drug Shows Promise in Relapsed/Refractory Myelomaon June 11, 2021 at 6:00 am
Treatment with an investigational drug induced high response rates in patients with relapsed or refractory multiple myeloma.
- FDA Grants Breakthrough Therapy Designation for Teclistamab to Treat Relapsed, Refractory Multiple Myelomaon June 10, 2021 at 1:46 pm
Teclistamab is an off-the-shelf, T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 receptors.
- CASI Pharmaceuticals Announces Dosing Of First Patient Of CID-103 In Phase 1 Clinical Trial For Relapsed Or Refractory Multiple Myelomaon June 10, 2021 at 4:00 am
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative ...
- Abecma Continues to Improve Survival in Heavily Pretreated Patients With Multiple Myelomaon June 6, 2021 at 1:00 pm
After long-term follow-up, the CAR-T cell therapy still boosted survival outcomes in patients with relapsed/refractory multiple myeloma, regardless of the number of prior lines of therapy received.
via Bing News